Does Rallies show Form 4 insider transactions for ESPR?

Yes. Rallies tracks ESPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ESPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ESPR. It does not provide personalized investment advice.

ESPR (Esperion Therapeutics, Inc.) Stock Analysis - Insider Trades

Esperion Therapeutics, Inc. (ESPR) is a publicly traded Healthcare sector company. As of May 21, 2026, ESPR trades at $3.13 with a market cap of $805.76M and a P/E ratio of -225901000000000000.00. ESPR moved +0.16% today. Year to date, ESPR is -17.85%; over the trailing twelve months it is +244.45%. Its 52-week range spans $0.69 to $4.18. Analyst consensus is neutral with an average price target of $2.92. Rallies surfaces ESPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ESPR stock inside the company?

Recent ESPR insider activity includes Looker Benjamin sold 5.71K, Koenig Sheldon L. sold 25.58K, Halladay Benjamin sold 6.42K, Looker Benjamin sold 1.69K, and Koenig Sheldon L. sold 48.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ESPR Key Metrics

Key financial metrics for ESPR
Metric	Value
Price	$3.13
Market Cap	$805.76M
P/E Ratio	-225901000000000000.00
EPS	$-0.00
Dividend Yield	0.00%
52-Week High	$4.18
52-Week Low	$0.69
Volume	2.04K
Avg Volume	0
Revenue (TTM)	$418.24M
Net Income	$-7.42M
Gross Margin	0.00%

Recent ESPR Insider Trades

Looker Benjamin sold 5.71K (~$15.43K) on Mar 17, 2026.
Koenig Sheldon L. sold 25.58K (~$69.55K) on Mar 17, 2026.
Halladay Benjamin sold 6.42K (~$17.38K) on Mar 17, 2026.
Looker Benjamin sold 1.69K (~$4.87K) on Jan 20, 2026.
Koenig Sheldon L. sold 48.24K (~$177.20K) on Dec 17, 2025.

Latest ESPR News

Esperion Sale at $3.16 Per Share Includes $100M CVRs, Faces Rights Probe — May 4, 2026
ARCHIMED to Buy Esperion for $1.1B at $3.16 per Share with $100M Milestones — May 1, 2026
Bempedoic Acid Cuts Ischemic Stroke Risk 22%, Shows Similar MACE Benefit in Autoimmune/Inflammatory Disease Patients — Mar 30, 2026
Esperion Reports 144% Revenue Surge to $168.4M, Agrees to Acquire Corstasis — Mar 10, 2026
Esperion to Acquire Corstasis for $75M, Adding FDA-Approved Nasal Diuretic — Mar 4, 2026

ESPR Analyst Consensus

7 analysts cover ESPR: 0 strong buy, 0 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.92.

Common questions about ESPR

Who is trading ESPR stock inside the company?: Recent ESPR insider activity includes Looker Benjamin sold 5.71K, Koenig Sheldon L. sold 25.58K, Halladay Benjamin sold 6.42K, Looker Benjamin sold 1.69K, and Koenig Sheldon L. sold 48.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ESPR?: Yes. Rallies tracks ESPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ESPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ESPR. It does not provide personalized investment advice.